ArticleCancer management and research2018

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?

Anna Forsythe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.